Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLSD
stocks logo

CLSD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
316.67K
+3.49%
-0.600
-60%
100.00K
-95.71%
-0.975
-40.91%
100.00K
-79.67%
-0.975
+1525%
Estimates Revision
The market is revising No Change the revenue expectations for Clearside Biomedical, Inc. (CLSD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -92.10%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-92.10%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Clearside Biomedical Inc (CLSD.O) is -0.12, compared to its 5-year average forward P/E of -11.29. For a more detailed relative valuation and DCF analysis to assess Clearside Biomedical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.29
Current PE
-0.12
Overvalued PE
9.11
Undervalued PE
-31.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.37
Undervalued EV/EBITDA
-0.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
109.99
Current PS
3.48
Overvalued PS
224.96
Undervalued PS
-4.98
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CLSD News & Events

Events Timeline

(ET)
2025-11-24
07:06:36
Clearside Biomedical to Seek Business Sale Through Chapter 11 Proceedings
select
2025-07-23 (ET)
2025-07-23
07:08:18
Clearside Biomedical announces approval of XIPERE in Canada
select
2025-07-17 (ET)
2025-07-17
07:10:19
Clearside Biomedical transitions all employees to consulting roles
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-24Benzinga
Nasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly

  • U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 350 points, while the Dow and S&P 500 also saw increases of 0.16% and 0.83%, respectively.

  • Sector Movements: Communication services stocks rose by 2.7%, while energy stocks experienced a decline of 0.9%.

  • Company Earnings Highlights: CureVac N.V. reported better-than-expected third-quarter earnings of $1.41 per share and sales of $63.295 million, surpassing analyst estimates.

  • Market Reactions: Enlivex Therapeutics shares surged 79% following a significant private placement announcement, while Clearside Biomedical shares plummeted 67% after filing for bankruptcy.

[object Object]
Preview
9.0
11-24Newsfilter
Clearside Biomedical Files for Chapter 11 Bankruptcy, Seeks Asset Auction
  • Bankruptcy Filing: Clearside Biomedical, Inc. has filed a voluntary petition for Chapter 11 bankruptcy in the Delaware Bankruptcy Court, indicating significant financial distress. This move may severely impact the company's operations and investor confidence moving forward.
  • Asset Auction Plan: The company intends to seek court approval for an asset auction process, allowing interested parties to submit bids for its assets. This auction aims to maximize stakeholder value but may also lead to asset fragmentation and uncertainty regarding the company's future.
  • Clinical Program Progress: Clearside's CLS-AX program is Phase 3-ready, targeting wet age-related macular degeneration (AMD) and diabetic retinopathy. The success of these trials will directly influence the company's future growth and market position.
  • Licensing and Collaboration Agreements: Clearside has established licensing agreements with various companies for its suprachoroidal injection platform, involving the development of ophthalmic therapeutics. These partnerships could provide potential future revenue streams, but their sustainability is challenged by the bankruptcy context.
[object Object]
Preview
9.0
11-24TipRanks
What’s Causing the Decline in Clearside Biomedical Stock (CLSD) Today?

  • Bankruptcy Filing: Clearside Biomedical (CLSD) announced its voluntary Chapter 11 bankruptcy filing, following a thorough evaluation of strategic options by its Board of Directors.

  • Asset Sale Plans: The company plans to sell all or part of its assets during the bankruptcy process, inviting binding offers that would be free of liens and interests, while seeking court permission to continue normal operations.

  • Stock Performance: Following the bankruptcy announcement, CLSD stock dropped 70.59% in pre-market trading, marking an 80.91% decline year-to-date and an 83.21% decrease over the past year.

  • Analyst Consensus: The current consensus rating for Clearside Biomedical is Hold, based on a single Hold rating, with no price target set, which may change as analysts reassess the situation post-bankruptcy news.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Clearside Biomedical Inc (CLSD) stock price today?

The current price of CLSD is 0.3515 USD — it has decreased -36.83 % in the last trading day.

arrow icon

What is Clearside Biomedical Inc (CLSD)'s business?

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

arrow icon

What is the price predicton of CLSD Stock?

Wall Street analysts forecast CLSD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLSD is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Clearside Biomedical Inc (CLSD)'s revenue for the last quarter?

Clearside Biomedical Inc revenue for the last quarter amounts to 201.00K USD, decreased -80.64 % YoY.

arrow icon

What is Clearside Biomedical Inc (CLSD)'s earnings per share (EPS) for the last quarter?

Clearside Biomedical Inc. EPS for the last quarter amounts to -1.14 USD, decreased -25.97 % YoY.

arrow icon

What changes have occurred in the market's expectations for Clearside Biomedical Inc (CLSD)'s fundamentals?

The market is revising No Change the revenue expectations for Clearside Biomedical, Inc. (CLSD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -92.10%.
arrow icon

How many employees does Clearside Biomedical Inc (CLSD). have?

Clearside Biomedical Inc (CLSD) has 32 emplpoyees as of December 05 2025.

arrow icon

What is Clearside Biomedical Inc (CLSD) market cap?

Today CLSD has the market capitalization of 95.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free